Egyptian pharmaceutical company Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has approved the redesignation of Amr Abdullah Morsi Mossad from Managing Director to Chief Executive Officer and Managing Director.

The decision was approved by the company's board of directors, formalising Mossad's position as both CEO and Managing Director.

The announcement was disclosed by Rameda under its Egyptian stock market ticker, RMDA.CA.

The board's decision marks an update to the company's executive leadership structure.

Source: Reuters